Platelet aggregation plays a pivotal role in the pathogenesis of cardiovascular diseases and rheumatoid arthritis. Nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly used for the prevention of such diseases. NSAIDs are associated with the severe risk of ulcer and bleeding disorders due to their acetylated chemical structure. Paracetamol is often regarded as NSAIDs. It is a nonacetylated monophenolic drug with mild anti-platelet and anti-inflammatory activity at high dose range which is clinically insignificant. In the current research work we evaluated the effects of 2-acetamidophenol, a positional isomer of paracetamol against in vitro human platelet aggregation and collagen induced rheumatoid arthritis model. We used two aggregating agents namely arachidonic acid and adenosine 5'- diphosphate against 2-acetamidophenol. Aggregation was monitored through a dual channel aggregometer. We found that 2-acetamidophenol has several times more potent anti-platelet and antiarthritic potential than aspirin. Our results demonstrate that 2-acetamidophenol may be a strong drug candidate for the prevention of cardiovascular diseases and rheumatoid arthritis.
Keywords: 2-acetamidophenol, nonsteroidal anti-inflammatory drugs, platelet aggregation, rheumatoid arthritis, collagen induced arthritis, arachidonic acid, adenosine 5'-diphosphate.